Adherex Technologies (FENC) Given News Impact Rating of 0.01

News coverage about Adherex Technologies (NASDAQ:FENC) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adherex Technologies earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.7658247820568 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Separately, Laidlaw started coverage on shares of Adherex Technologies in a report on Wednesday, November 29th. They issued a “buy” rating and a $22.00 price target on the stock.

Adherex Technologies (NASDAQ FENC) opened at $8.99 on Wednesday. Adherex Technologies has a twelve month low of $8.00 and a twelve month high of $13.95.

Adherex Technologies (NASDAQ:FENC) last released its earnings results on Monday, November 13th. The company reported ($0.15) EPS for the quarter. During the same quarter in the prior year, the company earned ($0.04) EPS.

ILLEGAL ACTIVITY NOTICE: This story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2017/12/06/adherex-technologies-fenc-given-news-impact-rating-of-0-01.html.

About Adherex Technologies

Fennec Pharmaceuticals Inc, formerly Adherex Technologies Inc, is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Insider Buying and Selling by Quarter for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply